8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Material company update
Dec 18, 2025·SEC
Neuphoria Therapeutics Inc.(NEUP)Earnings, Financials & Key Ratios
NEUP•NASDAQ
Price updated Jun 19, 2026
AboutNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Show more
- Revenue$16M
- EBITDA-$122K+99.5%
- Net Income-$370K+98.4%
- EPS (Diluted)-0.23-130.0%
- Gross Margin100%
- EBITDA Margin-0.78%
- Operating Margin-7.21%
- Net Margin-2.36%
- ROE-1.59%+98.9%
NEUP Key Insights
Neuphoria Therapeutics Inc. (NEUP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 40.3%
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 493.5% free cash flow margin
- ✓Strong 5Y sales CAGR of 244.9%
- ✓Share count reduced 98.9% through buybacks
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NEUP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NEUP Price & Volume
Neuphoria Therapeutics Inc. (NEUP) stock price & volume — 10-year historical chart
Loading chart...
NEUP Growth Metrics
Neuphoria Therapeutics Inc. (NEUP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.9%
5 Years244.91%
3 Years290.11%
TTM-140.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-363.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.92%
Return on Capital
10 Years-49.56%
5 Years-65.36%
3 Years-81.03%
Last Year-3.71%
NEUP Recent Earnings
Neuphoria Therapeutics Inc. (NEUP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)●Beat Revenue 3/12 qtrs (60%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.09+83.9%
$0.56
Rev
—
—
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.77-37.5%
$0.56
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$4.41-701.8%
$0.55
Rev
—
—
Q4 2025
Sep 29, 2025Metric
Actual
Est
EPS
$5.79-933.9%
$0.56
Rev
$16M-6026.1%
$264,300
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.09vs $0.56+83.9% | — |
| Q1 2026 | Feb 17, 2026 | $0.77vs $0.56-37.5% | — |
| Q4 2025 | Nov 14, 2025 | $4.41vs $0.55-701.8% | — |
| Q4 2025 | Sep 29, 2025 | $5.79vs $0.56-933.9% | $16Mvs $264,300-6026.1% |
Based on last 12 quarters of dataView full earnings history →
NEUP Peer Comparison
Neuphoria Therapeutics Inc. (NEUP) competitors in Clinical-Stage Biopharma Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 NRXP | 68.62M | 3.97 | -2.96 | -10.7% | ||||
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% |
Compare NEUP vs Peers
Neuphoria Therapeutics Inc. (NEUP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NEUP Income Statement
Neuphoria Therapeutics Inc. (NEUP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.13M | 2.76M | 2.68M | 32.06K | 0 | 263.61K | 0 | 0 | 15.65M | -10.47M |
Revenue Growth % | -20.79% | -33.25% | -2.86% | -98.8% | -100% | - | -100% | - | - | -140.09% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 165.69K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 4.13M▲ 0% | 2.76M▼ 33.3% | 2.68M▼ 2.9% | 32.06K▼ 98.8% | 0▼ 100.0% | 263.61K▲ 0% | 0▼ 100.0% | 0▲ 0% | 15.65M▲ 0% | -10.64M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | - | 100% | - | - | 100% | 101.58% |
Gross Profit Growth % | -20.79% | -33.25% | -2.86% | -98.8% | -100% | - | -100% | - | - | - |
Operating Expenses | 14.93M | 24.04M | 13.43M | 6.23M | 8.96M | 21.6M | 33.09M | 26.79M | 16.78M | 15.55M |
OpEx % of Revenue | 361.54% | 871.76% | 501.61% | 19419.28% | - | 8195.17% | - | - | 107.21% | - |
Selling, General & Admin | 5.72M | 4.97M | 6.55M | 3.33M | 4.24M | 0 | 13.41M | 0 | 7.77M | 7.18M |
SG&A % of Revenue | 138.52% | 180.15% | 244.58% | 10396.44% | - | - | - | - | 49.67% | - |
Research & Development | 18.61M | 18.55M | 6.29M | 4M | 4.33M | 16M | 19.67M | 14.1M | 9.01M | 6.72M |
R&D % of Revenue | 450.61% | 672.62% | 234.74% | 12489.64% | - | 6068.67% | - | - | 57.54% | - |
Other Operating Expenses | -9.4M | 523.58K | 596.83K | -1.11M | 386.74K | 5.61M | 0 | 12.69M | 0 | 791.38K |
Operating Income | -10.8M▲ 0% | -21.28M▼ 97.0% | -10.76M▲ 49.5% | -6.19M▲ 42.4% | -8.96M▼ 44.6% | -21.34M▼ 138.2% | -33.09M▼ 55.1% | -26.79M▲ 19.0% | -1.13M▲ 95.8% | -26.19M▲ 0% |
Operating Margin % | -261.54% | -771.76% | -401.61% | -19319.28% | - | -8095.17% | - | - | -7.21% | 250.04% |
Operating Income Growth % | 50.17% | -96.96% | 49.45% | 42.42% | -44.61% | -138.22% | -55.05% | 19.04% | 95.78% | - |
EBITDA | -9.06M | -19.61M | -9.05M | -4.52M | -7.68M | -20.23M | -32.09M | -25.79M | -121.9K | -25.3M |
EBITDA Margin % | -219.36% | -711.27% | -337.83% | -14082.87% | - | -7674.36% | - | - | -0.78% | 241.61% |
EBITDA Growth % | 54.1% | -116.43% | 53.86% | 50.1% | -70.08% | -163.42% | -58.62% | 19.62% | 99.53% | -1311.82% |
D&A (Non-Cash Add-back) | 1.74M | 1.67M | 1.71M | 1.68M | 1.28M | 1.11M | 998.17K | 992.56K | 1.01M | 883.39K |
EBIT | -3.27M | -17.77M | -5.28M | -2.91M | -5.79M | -21.92M | -32.45M | -26.64M | -1.13M | -23.62M |
Net Interest Income | -589K | -1.09M | -1.46M | -1.2M | -1.07M | -11.7K | 323.16K | 220.1K | 166.5K | 582.52K |
Interest Income | 925.02K | 422.32K | 197.95K | 39.13K | 4.29K | 6.79K | 323.16K | 220.1K | 166.5K | 582.52K |
Interest Expense | 1.51M | 1.51M | 1.66M | 1.24M | 1.08M | 18.48K | 0 | 0 | 0 | 0 |
Other Income/Expense | 6.02M | 2M | 3.82M | 2.05M | 2.28M | -609.57K | 695.55K | 3.46M | 291.09K | -1.66M |
Pretax Income | -4.79M▲ 0% | -19.28M▼ 302.9% | -6.94M▲ 64.0% | -4.14M▲ 40.3% | -6.68M▼ 61.2% | -21.95M▼ 228.8% | -32.39M▼ 47.6% | -23.32M▲ 28.0% | -838K▲ 96.4% | -27.85M▲ 0% |
Pretax Margin % | -115.84% | -699.27% | -259.02% | -12915.56% | - | -8326.42% | - | - | -5.35% | 265.94% |
Income Tax | 401.57K | -852.96K | -165.79K | -142.65K | -140.82K | -191.79K | -209.47K | -130.73K | -468.37K | -296.4K |
Effective Tax Rate % | -8.39% | 4.42% | 2.39% | 3.44% | 2.11% | 0.87% | 0.65% | 0.56% | 55.89% | 1.06% |
Net Income | -5.19M▲ 0% | -18.43M▼ 255.3% | -6.77M▲ 63.3% | -4.89M▲ 27.8% | -6.53M▼ 33.6% | -21.76M▼ 233.0% | -32.18M▼ 47.9% | -23.19M▲ 27.9% | -369.63K▲ 98.4% | -27.55M▲ 0% |
Net Margin % | -125.56% | -668.33% | -252.83% | -15255.18% | - | -8253.66% | - | - | -2.36% | 263.11% |
Net Income Growth % | 58.18% | -255.28% | 63.25% | 27.77% | -33.6% | -232.96% | -47.91% | 27.93% | 98.41% | -363.38% |
Net Income (Continuing) | -5.19M | -18.43M | -6.77M | -4M | -6.53M | -21.76M | -32.18M | -23.19M | -369.63K | -27.55M |
Discontinued Operations | 0 | 0 | 0 | -892.78K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.13▲ 0% | -0.46▼ 253.8% | -0.16▲ 65.2% | -0.11▲ 31.3% | -0.10▲ 9.1% | -0.13▼ 30.0% | -0.17▼ 30.8% | -0.10▲ 41.2% | -0.23▼ 130.0% | -5.09▲ 0% |
EPS Growth % | 60.61% | -253.85% | 65.22% | 31.25% | 9.09% | -30% | -30.77% | 41.18% | -130% | 36.92% |
EPS (Basic) | -0.13 | -0.46 | -0.16 | -0.11 | -0.10 | -0.13 | -0.17 | -0.10 | -0.23 | - |
Diluted Shares Outstanding | 40.11M | 40.19M | 43.44M | 45.41M | 65M | 112.78M | 122.39M | 149.8M | 1.62M | 5.41M |
Basic Shares Outstanding | 40.11M | 40.19M | 43.44M | 45.41M | 65M | 112.78M | 122.39M | 149.8M | 1.62M | 5.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NEUP Balance Sheet
Neuphoria Therapeutics Inc. (NEUP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 41.86M | 26.39M | 17.6M | 5.73M | 23.24M | 28.76M | 8.87M | 13.19M | 22.85M | 21.66M |
Cash & Short-Term Investments | 33.37M | 18.72M | 10.18M | 3.15M | 21.41M | 23.09M | 8.06M | 12.61M | 21.59M | 19.44M |
Cash Only | 32.95M | 18.31M | 9.79M | 3.15M | 21.41M | 23.09M | 8.06M | 12.61M | 21.59M | 19.44M |
Short-Term Investments | 422.65K | 404.02K | 385.19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 7.6M | 523.5K | 621.02K | 40.74K | 192.88K | 4.67M | 283.62K | 126.88K | 0 | 1.61M |
Days Sales Outstanding | 671.71 | 69.3 | 84.63 | 463.78 | - | 6.46K | - | - | - | -23.67 |
Inventory | 327.16K | 360.02K | 465.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 2.02K | 6.09M | 5.49M | 2.01M | 984.28K | 0 | 0 | 351 | 136.58K | 611.91K |
Total Non-Current Assets | 22.74M | 21.41M | 19.98M | 17.95M | 17.53M | 16.17M | 10.52M | 14.46M | 20.59M | 13.15M |
Property, Plant & Equipment | 2.01M | 2.02M | 1.76M | 724.9K | 654.37K | 464.01K | 221.66K | 218.97K | 160.12K | 0 |
Fixed Asset Turnover | 2.05x | 1.37x | 1.53x | 0.04x | - | 0.57x | - | - | 97.74x | -176.07x |
Goodwill | 9.42M | 9.16M | 8.94M | 8.84M | 9.32M | 8.85M | 5.79M | 8.69M | 13.13M | 8.84M |
Intangible Assets | 11.01M | 9.95M | 9.02M | 8.08M | 7.47M | 6.77M | 4.08M | 5.47M | 7.3M | 4.31M |
Long-Term Investments | 295.08K | 282.08K | 384K | 436.17K | 119K | 0 | 52.52K | 78.83K | 0 | 0 |
Other Non-Current Assets | 0 | 0 | -115.07K | -136.47K | -29.59K | 81.86K | 0 | -795 | 0 | 0 |
Total Assets | 64.61M▲ 0% | 47.8M▼ 26.0% | 37.58M▼ 21.4% | 23.68M▼ 37.0% | 40.77M▲ 72.2% | 44.93M▲ 10.2% | 19.39M▼ 56.8% | 27.65M▲ 42.6% | 43.44M▲ 57.1% | 34.81M▲ 0% |
Asset Turnover | 0.06x | 0.06x | 0.07x | 0.00x | - | 0.01x | - | - | 0.36x | -0.29x |
Asset Growth % | -1.7% | -26.02% | -21.38% | -36.99% | 72.17% | 10.2% | -56.83% | 42.57% | 57.11% | 191.21% |
Total Current Liabilities | 10.67M | 9.76M | 9.67M | 5.68M | 1.77M | 2.31M | 1.82M | 3.83M | 6.41M | 1.51M |
Accounts Payable | 1.46M | 2.65M | 842.3K | 866.78K | 772.93K | 1.07M | 958.06K | 2.24M | 1.75M | 627.18K |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 2.5K |
Short-Term Debt | 6.53M | 4.29M | 5.92M | 3.56M | 0 | 0 | 97.9K | 33.12K | 49.76K | 34.23K |
Deferred Revenue (Current) | 14.99K | 64.17K | 158.09K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.31M | 1.1M | 654.1K | 267.17K | 279.45K | 281.57K | 385.59K | 328.89K | 54.33K | 851.9K |
Current Ratio | 3.92x | 2.70x | 1.82x | 1.01x | 13.10x | 12.46x | 4.87x | 3.45x | 3.56x | 14.31x |
Quick Ratio | 3.89x | 2.67x | 1.77x | 1.01x | 13.10x | 12.46x | 4.87x | 3.45x | 3.56x | 14.31x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -2.52K |
Total Non-Current Liabilities | 22.85M | 25.58M | 15.52M | 9.28M | 3.23M | 3.47M | 2.92M | 6.33M | 8.15M | 3.87M |
Long-Term Debt | 7.69M | 11.56M | 6.06M | 4.3M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 17.48K | 521.14K | 367.06K | 159.65K | 117.63K | 0 | 0 |
Deferred Tax Liabilities | 3.67M | 2.21M | 2.06M | 1.51M | 1.38M | 1.24M | 1.11M | 963.54K | 0 | 1.28M |
Other Non-Current Liabilities | 11.49M | 11.81M | 7.4M | 3.45M | 1.33M | 1.86M | 1.64M | 5.25M | 8.15M | 3.48M |
Total Liabilities | 33.52M | 35.34M | 25.18M | 14.97M | 5.01M | 5.78M | 4.74M | 10.16M | 14.57M | 5.39M |
Total Debt | 14.22M | 15.85M | 11.98M | 8.41M | 652.04K | 477.15K | 257.55K | 272.74K | 226.49K | 34.23K |
Net Debt | -18.72M | -2.47M | 2.18M | 5.26M | -20.76M | -22.61M | -7.8M | -12.34M | -21.37M | -19.41M |
Debt / Equity | 0.46x | 1.27x | 0.97x | 0.96x | 0.02x | 0.01x | 0.02x | 0.02x | 0.01x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.77x |
Interest Coverage | -2.16x | -11.75x | -3.19x | -2.35x | -5.38x | -1185.93x | - | - | - | - |
Total Equity | 31.09M▲ 0% | 12.46M▼ 59.9% | 12.39M▼ 0.5% | 8.71M▼ 29.7% | 35.76M▲ 310.4% | 39.15M▲ 9.5% | 14.65M▼ 62.6% | 17.49M▲ 19.4% | 28.87M▲ 65.1% | 29.42M▲ 0% |
Equity Growth % | -1.9% | -59.93% | -0.5% | -29.7% | 310.39% | 9.48% | -62.58% | 19.37% | 65.08% | 167.59% |
Book Value per Share | 0.77 | 0.31 | 0.29 | 0.19 | 0.55 | 0.35 | 0.12 | 0.12 | 17.79 | 5.44 |
Total Shareholders' Equity | 31.09M | 12.46M | 12.39M | 8.71M | 35.76M | 39.15M | 14.65M | 17.49M | 28.87M | 29.42M |
Common Stock | 103.38M | 99.33M | 101.51M | 101.8M | 142.9M | 149.75M | 0 | 0 | 29 | 54 |
Retained Earnings | -83.14M | -96.49M | -98.65M | -102.3M | -115.74M | -119.22M | -108.16M | -177.98M | -270.98M | -186.89M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 10.85M | 9.62M | 9.54M | 9.22M | 8.6M | 8.62M | 3.2M | -3.01M | -4.32M | -2.07M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NEUP Cash Flow Statement
Neuphoria Therapeutics Inc. (NEUP) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.44M | -15.02M | -10.91M | -2.68M | -5.66M | -14.97M | -9.85M | -14.68M | 77.23M | 59.46M |
Operating CF Margin % | -34.86% | -544.91% | -407.43% | -8364.92% | - | -5677.36% | - | - | 493.49% | - |
Operating CF Growth % | 90.63% | -943.48% | 27.37% | 75.42% | -111.19% | -164.22% | 34.21% | -49.11% | 626.05% | 2332.37% |
Net Income | 0 | 0 | 0 | -4.89M | -6.53M | -14.97M | -14.38M | -15.49M | -369.63M | -27.55M |
Depreciation & Amortization | 0 | 0 | 0 | 1.68M | 1.28M | 763.17K | 446.09K | 662.99K | 662.89M | 662.89M |
Stock-Based Compensation | 0 | 0 | 0 | 38.03K | 983.01K | 1.95M | 0 | 814.81K | 163.77M | 163.91M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -468.43M | -468.54M |
Other Non-Cash Items | -1.44M | -15.02M | -10.91M | -2.28M | -2.62M | 1.15M | 1.01M | -2.12M | 89.12M | 91.77M |
Working Capital Changes | 970.52K | 63.96K | -480.02K | 2.77M | 1.23M | -3.85M | 3.08M | 1.46M | -496.83K | -3.88M |
Change in Receivables | 0 | 0 | 0 | 2.71M | 1.52M | -4.01M | 2.78M | 299.2K | 114.94K | 112.62M |
Change in Inventory | 0 | 0 | 0 | -19.44K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 251.69K | 804.37K | -917.66K | -917.14M |
Cash from Investing | 733.05K | 59.68K | 138.42K | -134.08K | -60.26K | 427.68K | 0 | 0 | 0 | 0 |
Capital Expenditures | -190.2K | -358.11K | -69.28K | -5.29K | -1.1K | -1.06K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 4.6% | 12.99% | 2.59% | 16.51% | - | 0.4% | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | -692.61K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 923.25K | 417.79K | 207.71K | 221.76K | 29.85K | 129.06K | 0 | 0 | 0 | 0 |
Cash from Financing | -1.6M | 1.94M | 3.05M | -3.68M | 23.71M | 18.57M | 2.6M | 15.11M | 1.53B | 1.55B |
Debt Issued (Net) | -1.71M | 1.63M | -3.73M | -5.69M | -8.92M | -119.85K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 110.36K | 302.03K | 7.07M | 2.24M | 32.94M | 22.63M | 2.6M | 10.11M | 1.53M | 25.17M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -420.37K | -48.23K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -294.4K | -226.68K | -312.17K | -3.94M | 0 | 5M | 1.53B | 1.52B |
Net Change in Cash | -2.58M▲ 0% | -13.18M▼ 411.5% | -7.67M▲ 41.8% | -6.46M▲ 15.7% | 17.97M▲ 378.0% | 3.48M▼ 80.6% | -15.02M▼ 531.2% | 504.99K▲ 103.4% | 1.6B▲ 317084.9% | 14.27B▲ 0% |
Free Cash Flow | -1.3M▲ 0% | -15.38M▼ 1086.3% | -10.98M▲ 28.6% | -2.69M▲ 75.5% | -5.67M▼ 110.8% | -14.97M▼ 164.2% | -9.85M▲ 34.2% | -14.68M▼ 49.1% | 77.23M▲ 626.0% | 59.46M▲ 0% |
FCF Margin % | -31.39% | -557.89% | -410.02% | -8381.43% | - | -5677.76% | - | - | 493.49% | -567.82% |
FCF Growth % | 88.84% | -1086.33% | 28.61% | 75.53% | -110.82% | -164.19% | 34.21% | -49.11% | 626.05% | 9025.02% |
FCF per Share | -0.03 | -0.38 | -0.25 | -0.06 | -0.09 | -0.13 | -0.08 | -0.10 | 47.59 | 10.99 |
FCF Conversion (FCF/Net Income) | 0.28x | 0.82x | 1.61x | 0.55x | 0.87x | 0.69x | 0.31x | 0.63x | -208.93x | -2.16x |
Interest Paid | 1.95M | 1.93M | 1.93M | 1.34M | 726.42K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 65.68K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NEUP Key Ratios
Neuphoria Therapeutics Inc. (NEUP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -16.52% | -84.64% | -54.5% | -46.34% | -29.38% | -58.09% | -119.63% | -144.32% | -1.59% | -109.66% |
Return on Invested Capital (ROIC) | -60.53% | -142.8% | -65.69% | -32.54% | -46.37% | -101.49% | -212.18% | -334.63% | -13.38% | -326.18% |
Gross Margin | 100% | 100% | 100% | 100% | - | 100% | - | - | 100% | 101.58% |
Net Margin | -125.56% | -668.33% | -252.83% | -15255.18% | - | -8253.66% | - | - | -2.36% | 263.11% |
Debt / Equity | 0.46x | 1.27x | 0.97x | 0.96x | 0.02x | 0.01x | 0.02x | 0.02x | 0.01x | 0.00x |
Interest Coverage | -2.16x | -11.75x | -3.19x | -2.35x | -5.38x | -1185.93x | - | - | - | - |
FCF Conversion | 0.28x | 0.82x | 1.61x | 0.55x | 0.87x | 0.69x | 0.31x | 0.63x | -208.93x | -2.16x |
Revenue Growth | -20.79% | -33.25% | -2.86% | -98.8% | -100% | - | -100% | - | - | -140.09% |
Related:NEUP Dividend History·NEUP Revenue History·NEUP Price History·NEUP P/E History·NEUP Financial Ratios·NEUP Institutional Holders
NEUP SEC Filings & Documents
Neuphoria Therapeutics Inc. (NEUP) SEC filings — annual & quarterly reports (10-K, 10-Q)
NEUP Frequently Asked Questions
Neuphoria Therapeutics Inc. (NEUP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Neuphoria Therapeutics Inc. (NEUP) reported $-10.5M in revenue for fiscal year 2025.
Neuphoria Therapeutics Inc. (NEUP) grew revenue by 0.0% over the past year. Growth has been modest.
Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $27.6M for fiscal year 2025.
Dividend & Returns
Neuphoria Therapeutics Inc. (NEUP) has a return on equity (ROE) of -1.6%. Negative ROE indicates the company is unprofitable.
Neuphoria Therapeutics Inc. (NEUP) generated $59.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.